{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:33Z","timestamp":1753891773897,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.544789","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T14:10:51Z","timestamp":1600265451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Xiaoling","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma. (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma. (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden. (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels","volume":"144","author":"Endris","year":"2019","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","article-title":"Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications","volume":"25","author":"Suraokar","year":"2014","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"D470","DOI":"10.1093\/nar\/gku1204","article-title":"The BioGRID interaction database: 2015 update","volume":"43","author":"Chatr-Aryamontri","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"D449","DOI":"10.1093\/nar\/gkh086","article-title":"The database of interacting proteins: 2004 update","volume":"32","author":"Salwinski","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"D767","DOI":"10.1093\/nar\/gkn892","article-title":"Human protein reference database\u22122009 update","volume":"37","author":"Keshava Prasad","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/gb-2007-8-5-r95","article-title":"Unequal evolutionary conservation of human protein interactions in interologous networks","volume":"8","author":"Brown","year":"2007","journal-title":"Genome Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"D358","DOI":"10.1093\/nar\/gkt1115","article-title":"The MIntAct project\u2013IntAct as a common curation platform for 11 molecular interaction databases","volume":"42","author":"Orchard","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"D857","DOI":"10.1093\/nar\/gkr930","article-title":"MINT, the molecular interaction database: 2012 update","volume":"40","author":"Licata","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/gb-2010-11-5-r53","article-title":"A human functional protein interaction network and its application to cancer data analysis","volume":"11","author":"Wu","year":"2010","journal-title":"Genome Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.12688\/f1000research.4431.2","article-title":"ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis","volume":"3","author":"Wu","year":"2014","journal-title":"F1000Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: new perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"D377","DOI":"10.1093\/nar\/gks1118","article-title":"PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees","volume":"41","author":"Mi","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"D674","DOI":"10.1093\/nar\/gkn653","article-title":"PID: the pathway interaction database","volume":"37","author":"Schaefer","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.101415","article-title":"Mining TCGA database for genes of prognostic value in glioblastoma microenvironment","volume":"10","author":"Jia","year":"2018","journal-title":"Aging."},{"key":"B29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","article-title":"Targeting tumor microenvironment for cancer therapy","volume":"20","author":"Roma-Rodrigues","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2217\/fon-2017-0234","article-title":"Is immunotherapy a viable option in treating mesothelioma?","volume":"13","author":"Dumoulin","year":"2017","journal-title":"Future Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2174\/1389450121666200719011234","article-title":"Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma","author":"Cheng","year":"2020","journal-title":"Curr Drug Targets"},{"key":"B32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/nov157","article-title":"The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities","volume":"18","author":"Silver","year":"2016","journal-title":"Neuro Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol"},{"article-title":"First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743. In: Abstract #3, WCLC 2020, Virtual 2020 Presidential Symposium, October 8, 2020","year":"2020","author":"Paul","key":"B34"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1008250","DOI":"10.1371\/journal.pgen.1008250","article-title":"Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma","volume":"15","author":"Gluck","year":"2019","journal-title":"PLoS Genet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3892\/ijo.2018.4605","article-title":"Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells","volume":"54","author":"Furlan","year":"2019","journal-title":"Int J Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/jcb.27446","article-title":"ETS1 induces transforming growth factor beta signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells","volume":"120","author":"Rodgers","year":"2019","journal-title":"J Cell Biochem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.21873\/anticanres.12601","article-title":"ETS-1 expression is hypoxia-independent in glioblastoma-derived endothelial and mesenchymal stem-like cells","volume":"38","author":"Koessinger","year":"2018","journal-title":"Anticancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/gcc.20948","article-title":"FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer","volume":"51","author":"Paulo","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/PAI.0000000000000227","article-title":"Increased FLI-1 expression is associated with poor prognosis in non-small cell lung cancers","volume":"24","author":"Lin","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neo.2014.08.007","article-title":"FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression","volume":"16","author":"Scheiber","year":"2014","journal-title":"Neoplasia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1182\/blood-2011-04-348052","article-title":"Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia","volume":"118","author":"Kornblau","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.544789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T14:10:54Z","timestamp":1600265454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.544789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":42,"alternative-id":["10.3389\/fonc.2020.544789"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.544789","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"article-number":"544789"}}